Daraxonrasib Toxicity Prevention and Management in Pancreatic Cancer

Authored by Shubham Pant, published on 2026-09-25 19:18:30.0

This algorithm is broadly aligned with current practice for managing adverse events of targeted oral therapies, and it closely follows the daraxonrasib (RASONQUE) FDA label for dosing, holds, dose reductions, and key serious risks (ILD/pneumonitis, GI perforation) in metastatic pancreatic adenocarcinoma. The core toxicity pathways (rash, stomatitis, diarrhea) and the dose-reduction ladder mirror prescribing-information-directed approaches and are consistent with CTCAE-based grading. The prophylaxis steps (skin regimen; consideration of tetracycline-class antibiotics) are reasonable and commonly used for acneiform/EGFR-like rashes, though evidence for prophylaxis may be extrapolated and not always trial-mandated for this agent.

  1. Confirm mPDAC after prior therapy or when multiagent therapy is unsuitable
    FDA-approved for metastatic pancreatic adenocarcinoma after ≥1 prior systemic therapy or when multiagent systemic therapy is not appropriate. The U.S. indication is not restricted by RAS mutation status and does not require a companion diagnostic.
    • Baseline clinical and laboratory assessment
      Complete the pretreatment laboratory assessment and document baseline skin, oral, gastrointestinal and hydration status before starting daraxonrasib. Essential baseline laboratory tests: CBC with differential and platelets CMP, including renal function, glucose, calcium, albumin, AST, ALT, ALP, and total bilirubin Magnesium, Phosphate, Lipase ± amylase Pregnancy test when applicable PDAC disease monitoring: CA 19-9 to establish a pretreatment baseline; interpret cautiously in patients with biliary obstruction/cholestasis or Lewis-antigen-negative disease CEA to obtain if CA 19-9 is non-elevated or otherwise uninformative Interpret bilirubin and CA 19-9 in the context of biliary obstruction and biliary drainage/stent status Additional tests as clinically indicated: PT/INR and aPTT for hepatic dysfunction, bleeding risk, anticoagulation, or planned invasive procedure HbA1c for known diabetes, hyperglycemia, or increased risk for diabetes CRP when clinically useful for evaluating inflammation/infection or establishing a disease-related baseline; not required routinely LDH when clinically useful for disease assessment/prognosis; not required routinely Hepatic function: Daraxonrasib exposure is not meaningfully altered in mild or moderate hepatic impairment. Pharmacokinetics in severe hepatic impairment have not been established.
      • Review concomitant medications and drug interactions
        Avoid: Strong CYP3A inhibitors with P-gp inhibition and systemic cyclosporine A. Strong CYP3A inducers when possible; dose adjustment is required if unavoidable. Systemic cyclosporine A/derivatives Separate P-gp substrates from daraxonrasib by at least 4 hours Drug interaction dose adjustments: Strong CYP3A inhibitor without P-gp inhibition: reduce to 150 mg once daily Moderate CYP3A inhibitor + P-gp inhibition: reduce to 100 mg once daily Moderate CYP3A inhibitor without P-gp inhibition: reduce to 200 mg once daily P-gp inhibitor: reduce to 150 mg once daily
        • Start dermatologic prophylaxis before first dose
          Start dermatologic prophylaxis before the first daraxonrasib dose; continue during treatment as clinically appropriate: Face: Hydrocortisone 2.5% cream — apply a thin layer to the face twice daily Chest: Triamcinolone acetonide 0.1% cream — apply a thin layer to the chest twice daily Moisturizer: Apply a fragrance-free emollient moisturizing cream (e.g., CeraVe Moisturizing Cream, Vanicream Moisturizing Cream, or equivalent) liberally to dry skin at least twice daily and after bathing. Sun protection: Apply broad-spectrum SPF ≥30 sunscreen to exposed skin ≥30 minutes before sun exposure; reapply every 2 hours while outdoors. Limit sun exposure and use protective clothing/hat. Oral antibiotic: Doxycycline 100 mg PO twice daily or minocycline 50 mg PO twice daily
          • Start daraxonrasib 300 mg once daily (with or without food, swallow tablets whole)
            Take daraxonrasib at the same time each day. Swallow tablets whole; do not chew, crush or split. If a dose is missed by >4 hours, skip it and take the next dose at the regularly scheduled time. If vomiting occurs after a dose, do not take an additional dose.
            • Monitor toxicity at 2 weeks, 4 weeks and then every 4 weeks if stable
              Toxicity needs to be evaluated within the first month of starting therapy. Best is to see the patient within 2 weeks of first dose. Again at 4 weeks and then every 8 weeks if the patient is doing well. Median onset in the label is only 3 days for diarrhea, 13 days for dermatologic toxicity, and 22 days for stomatitis. Practical monitoring schedule: Repeat CBC, renal/electrolyte profile, AST/ALT/ALP/bilirubin/albumin, corrected calcium and magnesium approximately every 2 weeks during the first 8 weeks. If stable, repeat approximately every 4 weeks thereafter. Check sooner for significant diarrhea, reduced oral intake, dehydration, new toxicity or prior laboratory abnormalities The U.S. Prescribing Information does not mandate a fixed laboratory monitoring interval.
              • New or worsening toxicity requiring intervention?
                Assess CTCAE grade, symptom burden, oral intake/hydration, relevant laboratory abnormalities and serious red flags. Toxicity-specific grading, AE management and dose modifications are within each specific AE branch below.
                • Yes
                  • Rash
                    Rash / dermatologic toxicity. 87% overall; Grade 3–4 13% Assess extent, symptoms, skin integrity and impact on daily activities Dermatologic toxicity may include rash, pruritus, paronychia, dry skin and skin fissures Median time to first onset: 13 days
                    • Grade 2 Toxicity: Obtain Dermatology Consultation
                      • Topical corticosteroid ± doxycycline/minocycline
                        Continue or intensify topical corticosteroid and emollient therapy. If not already receiving an oral antibiotic, consider doxycycline or minocycline as clinically appropriate. RASolute protocol prophylaxis used doxycycline 100 mg twice daily or minocycline 50 mg twice daily. Grade 2: Consider withholding daraxonrasib until recovery to ≤Grade 1 Resume at the same or next lower dose Grade 3: Withhold until recovery to ≤Grade 1 Consider dermatology consultation Resume at the next lower dose Grade 4: Permanently discontinue daraxonrasib
                        • Grade toxicity and apply AE-specific dose modification
                          Most toxicity-specific restart criteria require recovery to ≤Grade 1. For rash, stomatitis and diarrhea, the label permits some Grade 2 events to resume at the same or next lower dose after improvement. For other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required.
                          • Continue daraxonrasib at current dose
                            Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Resume at next lower dose: 300 → 200 → 150 mg once daily
                            How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                            Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                          • Implement withhold and restart plan
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Stomatitis / oral toxicity
                    Stomatitis / oral toxicity. 56% overall; Grade 3–4 12%. Assess grade and impact: mouth pain, mouth soreness, dysgeusia, oral mucositis, oral intake and hydration. Median time to first onset: 22 days.
                    • Stomatitis: start dexamethasone mouthwash
                      Continue oral care. Supportive regimen: Dexamethasone 0.5 mg/5 mL mouthwash: 10 mL TID; swish and spit. No food or drink for 30 minutes after use Reserve clotrimazole for suspected or confirmed candidiasis Daraxonrasib modification: Grade 2: consider withholding until recovery to ≤Grade 1; resume at the same or next lower dose Grade 3: withhold until recovery to ≤Grade 1; resume at the next lower dose Grade 4: permanently discontinue
                      • Grade toxicity and apply AE-specific dose modification
                        Most toxicity-specific restart criteria require recovery to ≤Grade 1. For rash, stomatitis and diarrhea, the label permits some Grade 2 events to resume at the same or next lower dose after improvement. For other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required.
                        • Continue daraxonrasib at current dose
                          Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Resume at next lower dose: 300 → 200 → 150 mg once daily
                          How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                          Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Implement withhold and restart plan
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Diarrhea
                    Diarrhea. 67% overall; Grade 3–4 7% Assess stool frequency, duration, oral intake, hydration and clinically relevant electrolyte or renal abnormalities. Median time to first onset: 3 days.
                    • Start loperamide (4 mg initially, then 2 mg) + hydration
                      Start antidiarrheal therapy promptly. Supportive regimen: Loperamide 4 mg initially, then 2 mg after each loose stool; maximum 16 mg/day Maintain oral or IV hydration and replace electrolytes as clinically indicated Add antiemetics as needed Daraxonrasib modification: Grade 2 persistent or intolerable: consider withholding until recovery to ≤Grade 1; resume at the same or next lower dose Grade 3: withhold until recovery to ≤Grade 1; resume at the next lower dose Grade 4: permanently discontinue
                      • Grade toxicity and apply AE-specific dose modification
                        Most toxicity-specific restart criteria require recovery to ≤Grade 1. For rash, stomatitis and diarrhea, the label permits some Grade 2 events to resume at the same or next lower dose after improvement. For other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required.
                        • Continue daraxonrasib at current dose
                          Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Resume at next lower dose: 300 → 200 → 150 mg once daily
                          How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                          Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Implement withhold and restart plan
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Suspected ILD/pneumonitis or GI perforation. HOLD daraxonrasib and urgently evaluate
                    New or worsening dyspnea, cough or fever: Withhold daraxonrasib and evaluate for ILD/pneumonitis Severe or persistent abdominal pain or clinical concern for perforation: Withhold daraxonrasib and urgently evaluate for gastrointestinal perforation ILD/pneumonitis: Frequency 2.4%; typically ~4 months after starting treatment (median 111 days; range 22–242) Grade 2: hold to ≤Grade 1; if appropriate, resume one dose lower Recurrent Grade 2 or Grade 3–4: permanently discontinue GI perforation: Frequency 0.9%; typically ~4–5 months after starting treatment (median 134 days; range 17–254). Grade 3: hold to ≤Grade 1; if appropriate, resume one dose lower Grade 4: permanently discontinue
                    • ILD/pneumonitis: Grade 2 → hold to ≤Grade 1; if appropriate, resume one dose lower
                      • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                        Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                    • GI perforation: Grade 3 → hold to ≤Grade 1; if appropriate, resume one dose lower
                      This approach follows the label, although rechallenge after perforation is clinically high risk and should be individualized after full recovery.
                      • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                        Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                    • Recurrent Grade 2 or Grade 3–4
                      • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                        Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                  • Grade ≥3 laboratory or other clinically significant toxicity. Evaluate cause and severity
                    Evaluate relevant laboratory abnormalities and alternative/contributing causes, including disease-related factors, dehydration and concomitant medications. Grade according to CTCAE v5.0. Transaminase ↑, bilirubin ↑, cytopenias. Assess grade and trends.
                    • Other Grade 3 toxicity: hold to ≤G1/baseline + lower dose; Grade 4: discontinue
                      Grade 3: Withhold daraxonrasib until recovery to ≤Grade 1 or baseline Resume at the next lower dose Grade 4: Permanently discontinue Address reversible or competing causes before resumption when clinically appropriate.
                      • Grade toxicity and apply AE-specific dose modification
                        Most toxicity-specific restart criteria require recovery to ≤Grade 1. For rash, stomatitis and diarrhea, the label permits some Grade 2 events to resume at the same or next lower dose after improvement. For other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required.
                        • Continue daraxonrasib at current dose
                          Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Resume at next lower dose: 300 → 200 → 150 mg once daily
                          How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                          Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Implement withhold and restart plan
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Nausea/Vomiting
                    Nausea: 52% | Grade 3–4: 3%; Vomiting: 42% | Grade 3–4: 1%
                    • Start antiemetic (e.g., ondansetron); maintain hydration and correct electrolyte abnormalities
                      Supportive treatment Ondansetron 8 mg PO every 8–12 hours PRN is a reasonable first-line option If persistent despite a 5-HT3 antagonist, add or switch antiemetic therapy based on symptoms, e.g. prochlorperazine 10 mg PO every 6 hours PRN or olanzapine 2.5–5 mg PO daily/at bedtime Daraxonrasib modification: Grade 1–2 Continue daraxonrasib; supportive antiemetic therapy and monitoring Grade 3 Hold daraxonrasib until recovery to ≤Grade 1; initiate/modify antiemetic therapy; resume at the next lower dose Grade 4 Permanently discontinue daraxonrasib
                      • Grade toxicity and apply AE-specific dose modification
                        Most toxicity-specific restart criteria require recovery to ≤Grade 1. For rash, stomatitis and diarrhea, the label permits some Grade 2 events to resume at the same or next lower dose after improvement. For other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required.
                        • Continue daraxonrasib at current dose
                          Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Resume at next lower dose: 300 → 200 → 150 mg once daily
                          How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                        • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                          Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                        • Implement withhold and restart plan
                          • Ongoing daraxonrasib monitoring at the tolerated dose
                            Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                  • Paronychia
                    Paronychia is included among the dermatologic manifestations of daraxonrasib toxicity, although this node does not provide a distinct treatment pathway.
                    • Grade 2 Toxicity: Obtain Dermatology Consultation
                      • Topical corticosteroid ± doxycycline/minocycline
                        Continue or intensify topical corticosteroid and emollient therapy. If not already receiving an oral antibiotic, consider doxycycline or minocycline as clinically appropriate. RASolute protocol prophylaxis used doxycycline 100 mg twice daily or minocycline 50 mg twice daily. Grade 2: Consider withholding daraxonrasib until recovery to ≤Grade 1 Resume at the same or next lower dose Grade 3: Withhold until recovery to ≤Grade 1 Consider dermatology consultation Resume at the next lower dose Grade 4: Permanently discontinue daraxonrasib
                        • Grade toxicity and apply AE-specific dose modification
                          Most toxicity-specific restart criteria require recovery to ≤Grade 1. For rash, stomatitis and diarrhea, the label permits some Grade 2 events to resume at the same or next lower dose after improvement. For other Grade 3 adverse reactions, recovery to ≤Grade 1 or baseline is required.
                          • Continue daraxonrasib at current dose
                            Applicable to selected Grade 2 rash, stomatitis or diarrhea after recovery to ≤Grade 1 when resumption at the same dose is clinically appropriate.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Resume at next lower dose: 300 → 200 → 150 mg once daily
                            How to dose reduce daraxonrasib: Starting dose: 300 mg once daily First reduction: 200 mg once daily (one 100 mg + one 100 mg) Second reduction: 150 mg once daily (one 150 mg) No further reduction below 150 mg Permanently discontinue if unable to tolerate 150 mg This ladder applies to adverse reactions; drug-interaction dose adjustments are different.
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                          • Permanently discontinue daraxonrasib when required by toxicity-specific label guidance
                            Permanent discontinuation is required for specified severe or recurrent toxicities and when 150 mg once daily cannot be tolerated. Follow the toxicity-specific prescribing information.
                          • Implement withhold and restart plan
                            • Ongoing daraxonrasib monitoring at the tolerated dose
                              Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
                • No
                  • Continue daraxonrasib at current dose
                    • Ongoing daraxonrasib monitoring at the tolerated dose
                      Continue clinical toxicity assessment and appropriate laboratory monitoring throughout treatment. Re-enter the toxicity pathway promptly if new or worsening adverse reactions develop.
  2. Patient Handout
    Report promptly: New or worsening rash, painful skin, blistering or extensive skin symptoms Mouth sores or difficulty eating/drinking New or worsening diarrhea New cough, dyspnea or fever Severe or persistent abdominal pain Daraxonrasib Patient Handout Download
  3. How to take daraxonrasib: 300 mg once daily, with or without food; swallow tablets whole
    Tablets are available as 100 mg and 150 mg Take at the same time each day Do not chew, crush or split tablets Missed by >4 hours: skip the dose Vomiting after a dose: do not repeat the dose
  4. Dose Reduction and Drug Interactions
    Adverse-reaction dose reductions: Starting dose: 300 mg once daily First reduction: 200 mg once daily Second reduction: 150 mg once daily Permanently discontinue if 150 mg once daily is not tolerated Common interacting medications: Apixaban / rivaroxaban (P-gp substrate), Amiodarone (CYP3A inhibitor), Diltiazem (moderate CYP3A inhibitor), Dexamethasone (CYP3A inducer) Drug-interaction dose adjustments follow a separate label-directed dosing scheme from the adverse-reaction dose-reduction ladder.
  5. Adverse reactions in RASolute 302: frequency and severity
    Rash: 87% | Grade 3–4: 13% Diarrhea: 67% | Grade 3–4: 7% Stomatitis: 56% | Grade 3–4: 12% Nausea: 52% | Grade 3–4: 3% Fatigue: 47% | Grade 3–4: 5% Vomiting: 42% | Grade 3–4: 1% Urgent red flags: New or worsening dyspnea, cough or fever, or severe/persistent abdominal pain should prompt immediate treatment interruption and urgent evaluation for ILD/pneumonitis or GI perforation.
tosprivacyFDA approves daraxonrasib for metastatic pancreatic adenocarcinoma. August 26, 2026.RASONQUE (daraxonrasib) Full Prescribing Information. Revolution Medicines. August 2026.NEJM PPT file - Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerPDF file - Protocol for: O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med 2026;395:325-37. DOI: 10.1056/NEJMoa2605555PDF file - Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerRASolute 302. ClinicalTrials.gov NCT06625320.Common Terminology Criteria for Adverse Events, Version 5.0RASONQUE Full Prescribing Information: Dosage Modifications and Drug Interactions